MedTrace Logo

Low-dose IL-2 Treatment on Behcet's Disease

NCT04065672 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-04-03

No results posted yet for this study

Summary

The study aims to explore the clinical and immunological efficacy of low-dose IL-2 on Behcet's Disease.

Conditions

  • Behcet's Disease

Interventions

DRUG

Low-dose IL-2

After a 4-week screening period, patients received IL-2 at a dose of 1 million IU subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.

DRUG

Placebo

After a 4-week screening period, patients received placebo subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.

Sponsors & Collaborators

  • HeJing

    lead OTHER

Principal Investigators

  • Zhanguo Li, MD,PhD · Department of Rheumatology and Immunology, Peking University People's Hospital.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-12
Primary Completion
2023-04-20
Completion
2023-07-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04065672 on ClinicalTrials.gov